Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotion, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. The company also provides other healthcare products, such as balms, nasal inhalers, over-the-counter products, petroleum jellies, roll-ons, shampoo, soaps, sprays, and vaginal washes. In addition, it offers therapeutic products consisting of analgesics, antacids, anxiolytics, and haematinics; anti-bacterials, antibiotics, anti-diabetics, anti-diarrheals, anti-emetics, antifungals, anti-haemorrhoidals, anti-helmintics, anti-infectives, anti-inflammatories, anti-malarials
| Current Price | ₹434.75 |
|---|---|
| Market Cap | ₹4,599 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Non-Prescription Drugs |
| P/E Ratio | 54.7 |
| Return on Equity | 8.62% |
| 52-Week Range | ₹127.90 – ₹455.95 |
| Beta (1Y) | 0.72 |
| Dividend Yield | 0.46% |
1. Pharmaceutical and Healthcare-100%
Bliss Gvs Pharma Ltd. is trading at ₹434.75, with a market capitalisation of ₹4,599 Cr.
Bliss Gvs Pharma Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Non-Prescription Drugs).
Bliss Gvs Pharma Ltd. has a P/E of 54.7 and a return on equity of 8.62%.